{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:02Z","timestamp":1753892042657,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the efficacy of liposomal prednisolone phosphate to mitigate the severity of proliferative vitreoretinopathy (PVR) in a minipig model of PVR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 18 eyes of 9 minipigs underwent PVR induction surgically. Eyes were randomized equally into three groups: intravitreal injection of liposomal prednisolone phosphate (LPP), triamcinolone acetonide (TA), and controls. PVR severity was graded on fundoscopic examination using a modified version of the Silicon Study Classification System. Severe PVR was defined as grade 2-5 on this classification, and the proportion of eyes with retinal detachment from severe PVR, defined as retinal re-detachment, i.e., PVR grade 2-5, was compared between treatment and control groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>On day 28, five eyes (83.3%) in the control group were observed to have severe PVR. Within the LPP group, one (16.7%) eye developed retinal detachment due to severe PVR. Grade 0 PVR was observed in four (66.7%) eyes, grade 1 in one (16.7%) eye, and grade 5 in one (16.7%) eye. Within the TA group, grade 0 PVR was observed in four eyes (66.7%), grade 1 in two eyes (16.6%), and grade 5 in one (16.7%) eye. The difference in the proportion of eyes with severe PVR was significantly lower in the LPP group compared to controls at day 28 (16.7% vs 83.3%, p=0.02). There was no significant difference in the rate of severe PVR or median PVR grade between the liposomal prednisolone phosphate and triamcinolone acetonide groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Liposomal prednisolone phosphate reduces the severity of PVR in a minipig model of PVR.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fopht.2023.1222689","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:54:25Z","timestamp":1700308465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of a steroid delivery system to mitigate the severity of proliferative vitreoretinopathy in a minipig model"],"prefix":"10.3389","volume":"3","author":[{"given":"Chee Wai","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna Marie Fianza","family":"Busoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amutha Barathi","family":"Veluchamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1981.03930010873017","article-title":"Human massive periretinal proliferation. In vitro characteristics of cellular components","volume":"99","author":"Newsome","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182a48900","article-title":"Trends and factors related to outcomes for primary rhegmatogenous retinal detachment surgery in a large asian tertiary eye center","volume":"34","author":"Wong","year":"2014","journal-title":"Retina"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200412000-00007","article-title":"Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy","volume":"24","author":"Patel","year":"2004","journal-title":"Retina"},{"key":"B4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000488492","article-title":"Animal models of proliferative vitreoretinopathy and their use in pharmaceutical investigations","volume":"60","author":"Hou","year":"2018","journal-title":"Ophthalmic Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: A prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20070901-02","article-title":"Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy","volume":"38","author":"Cheema","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150909100212","article-title":"Intravitreal steroids for the prevention of PVR after surgery for retinal detachment","volume":"21","author":"Gagliano","year":"2015","journal-title":"Curr Pharm Des"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-010-0807-z","article-title":"Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy","volume":"54","author":"Acar","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1319-8","article-title":"The effect of a preoperative subconjuntival injection of dexamethasone on blood-retinal barrier breakdown following scleral buckling retinal detachment surgery: a prospective randomized placebo-controlled double blind clinical trial","volume":"248","author":"Bali","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181fe5427","article-title":"Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy","volume":"31","author":"Chen","year":"2011","journal-title":"Retina"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/112067211002000224","article-title":"Effect of oral prednisolone on visual outcomes and complications after scleral buckling","volume":"20","author":"Dehghan","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1038\/s41598-019-51633-8","article-title":"Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy","volume":"9","author":"Wong","year":"2019","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313462","article-title":"Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema","volume":"103","author":"Wong","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1038\/s41598-018-24545-2","article-title":"Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.3390\/ijms21207794","article-title":"Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020","volume":"21","author":"Everts","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","article-title":"Platelet-induced vitreous membrane formation","volume":"12","author":"Constable","year":"1973","journal-title":"Invest Ophthalmol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1167\/tvst.9.9.46","article-title":"Endogenous or exogenous retinal pigment epithelial cells: A comparison of two experimental animal models of proliferative vitreoretinopathy","volume":"9","author":"Wong","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/BF02150154","article-title":"Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye","volume":"225","author":"Hida","year":"1987","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy : Results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050284","article-title":"Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease","volume":"237","author":"Hui","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00920223","article-title":"Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages","volume":"231","author":"Hui","year":"1993","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0192623318770379","article-title":"G\u00f6ttingen minipigs in ocular research","volume":"46","author":"Shrader","year":"2018","journal-title":"Toxicologic Pathol"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2023.1222689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:54:28Z","timestamp":1700308468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2023.1222689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":26,"alternative-id":["10.3389\/fopht.2023.1222689"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2023.1222689","relation":{},"ISSN":["2674-0826"],"issn-type":[{"type":"electronic","value":"2674-0826"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"article-number":"1222689"}}